Shire PLC (LON:SHP) traded up 0% during trading on Tuesday . The company traded as high as GBX 3,575 ($48.48) and last traded at GBX 3,549.09 ($48.13). 3,150,000 shares were traded during mid-day trading, an increase of 36% from the average session volume of 2,310,000 shares. The stock had previously closed at GBX 3,549.09 ($48.13).
A number of equities research analysts have recently commented on the company. Liberum Capital reissued a “hold” rating and issued a GBX 4,100 ($55.60) target price on shares of Shire in a research note on Monday. BNP Paribas reissued an “outperform” rating and issued a GBX 4,700 ($63.74) target price on shares of Shire in a research note on Tuesday. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Shire in a research note on Wednesday, January 10th. Deutsche Bank reissued a “buy” rating and issued a GBX 5,000 ($67.81) target price on shares of Shire in a research note on Thursday, January 11th. Finally, Shore Capital reissued a “buy” rating on shares of Shire in a research note on Monday. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. Shire currently has an average rating of “Buy” and a consensus target price of GBX 5,082.35 ($68.92).
The stock has a market capitalization of $32,140.00 and a price-to-earnings ratio of 2,792.97.
ILLEGAL ACTIVITY NOTICE: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.com-unik.info/2018/01/16/shire-shp-stock-price-up-0.html.
Shire Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.